FDA Adverse Event Malfunction Summary report: N

ARCHITECT ANTI-TPO

MDR report key: 23028501 · Received September 11, 2025

Report

Report Number
3008344661-2025-00129
Event Type
Malfunction
Date Received
September 11, 2025
Date of Event
September 4, 2025
Report Date
October 20, 2025
Manufacturer
ABBOTT IRELAND DIAGNOSTICS DIVISION
Product Code
JZO
UDI-DI
00380740003470
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

THIS REPORT IS BEING FILED ON AN INTERNATIONAL PRODUCT, LIST NUMBER 2K47-20 THAT HAS A SIMILAR PRODUCT DISTRIBUTED IN THE US, LIST NUMBER 2K47-27, WITH 510K/PMA/BLA NUMBER K052407. AN EVALUATION IS IN PROCESS. A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE EVALUATION IS COMPLETE.

Additional Manufacturer Narrative · 0

UPDATED TO INCLUDE DATES FOR D4 - EXPIRATION DATE AND H4 - DEVICE MFG DATE. THE COMPLAINT INVESTIGATION INCLUDED A REVIEW OF DATA AND INFORMATION PROVIDED BY THE CUSTOMER, SEARCH FOR SIMILAR COMPLAINTS, TICKET TRENDING REVIEW, DEVICE HISTORY RECORD REVIEW, IN HOUSE TESTING AND LABELING REVIEW. DATA AND INFORMATION PROVIDED BY THE CUSTOMER WERE REVIEWED AND SUPPORT THE COMPLAINT ISSUE. REVIEW OF TRACKING AND TRENDING FOR THE ARCHITECT ANTI-TPO ASSAY DID NOT IDENTIFY AN INCREASE IN COMPLAINT ACTIVITY RELATED TO THE COMPLAINT ISSUE. ADDITIONALLY, AN INCREASE IN COMPLAINT ACTIVITY WAS NOT IDENTIFIED FOR REAGENT LOT 42254UN24. A DEVICE HISTORY RECORD REVIEW DID NOT SHOW ANY POTENTIAL NON-CONFORMANCES, DEVIATIONS, OR NON-CONFORMANCES. IN HOUSE ACCURACY TESTING WAS PERFORMED TO EVALUATE THE PERFORMANCE OF REAGENT LOT 42254UN24. AN INTERNAL ARCHITECT ANTI-TPO PANEL SET WAS TESTED WITH A RETAINED KIT OF LOT 42254UN24. ALL VALIDITY AND ACCEPTANCE CRITERIA WERE MET, WHICH INDICATES ACCEPTABLE PRODUCT PERFORMANCE. LABELING WAS REVIEWED AND FOUND TO ADEQUATELY ADDRESS THE ISSUE UNDER REVIEW. BASED ON THE INVESTIGATION, NO SYSTEMIC ISSUE OR DEFICIENCY OF THE ARCHITECT ANTI-TPO REAGENT LOT 42254UN24 WAS IDENTIFIED.

Description of Event or Problem · 0

THE CUSTOMER OBSERVED A FALSELY DECREASED ARCHITECT ANTI-TPO RESULT GENERATED BY THE ARCHITECT I2000SR PROCESSING MODULE FOR A 26-YEAR-OLD FEMALE PATIENT WITH A HISTORY OF CHRONIC HIVES. THE FOLLOWING DATA WAS PROVIDED: CUSTOMER¿S REFERENCE RANGE: 0 TO 5.61 IU/ML. INITIAL ARCHITECT ANTI-TPO RESULT = 800.24 IU/ML. REPEAT #1 RESULT = 0.00 IU/ML. REPEAT #2 RESULT (POST HIGH-SPEED CENTRIFUGATION) = 839.12 IU/ML. OTHER RESULT PROVIDED: ANTI-TG RESULT = 63.66 IU/ML (REFERENCE RANGE: 0 TO 4.11 IU/ML). THE CUSTOMER CONSIDERED THE INITIAL ANTI-TPO RESULT OF 800.24 IU/ML TO BE CONSISTENT WITH THE PATIENT¿S CLINICAL PRESENTATION AND RELEASED IT TO THE PHYSICIAN. NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.

Description of Event or Problem · 0

THE CUSTOMER OBSERVED A FALSELY DECREASED ARCHITECT ANTI-TPO RESULT GENERATED BY THE ARCHITECT I2000SR PROCESSING MODULE FOR A 26-YEAR-OLD FEMALE PATIENT WITH A HISTORY OF CHRONIC HIVES. THE FOLLOWING DATA WAS PROVIDED: CUSTOMER¿S REFERENCE RANGE: 0 TO 5.61 IU/ML. INITIAL ARCHITECT ANTI-TPO RESULT = 800.24 IU/ML. REPEAT #1 RESULT = 0.00 IU/ML. REPEAT #2 RESULT (POST HIGH-SPEED CENTRIFUGATION) = 839.12 IU/ML. OTHER RESULT PROVIDED: ANTI-TG RESULT = 63.66 IU/ML (REFERENCE RANGE: 0 TO 4.11 IU/ML). THE CUSTOMER CONSIDERED THE INITIAL ANTI-TPO RESULT OF 800.24 IU/ML TO BE CONSISTENT WITH THE PATIENT¿S CLINICAL PRESENTATION AND RELEASED IT TO THE PHYSICIAN. NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2675018 ARCHITECT ANTI-TPO SYSTEM, TEST, THYROID AUTOANTIBODY JZO ABBOTT IRELAND DIAGNOSTICS DIVISION 42254UN24 00380740003470

Patients

Seq Age Sex Outcome Treatment
1 26 YR Female ARC I2000SR INST, 03M74-02,(B)(6)| ARC I2000SR INST, 03M74-02,(B)(6)